{"groups":[{"description":"Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery","id":"FG000","title":"Arm A: No Adjuvant Treatment"},{"description":"Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy","id":"FG001","title":"Arm B: Low Risk; Adjuvant Radiotherapy"},{"description":"High risk \\[metastatic, resected, incompletely resected, or unresected disease\\] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.\n\ndoxorubicin hydrochloride: Given IV\n\nclinical observation: Patients undergo observation\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nifosfamide: Given IV","id":"FG002","title":"Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy"},{"description":"High risk \\[metastatic, resected, incompletely resected, or unresected disease\\] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.\n\ndoxorubicin hydrochloride: Given IV\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nifosfamide: Given IV","id":"FG003","title":"Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"25"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"27"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"4"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"23"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"15"}],"type":"Refusal of further protocol therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"11"}],"type":"Inability to start week 16 tx on time"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"222"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"122"},{"groupId":"FG003","numSubjects":"223"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"205"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"96"},{"groupId":"FG003","numSubjects":"117"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"106"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}